AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib

Summary by AI BETAClose X

AIM ImmunoTech highlights Ampligen's potential in pancreatic cancer treatment, noting that in a selected patient population, Ampligen monotherapy was associated with a median overall survival of 34.8 months, significantly higher than the 12.5 months observed in historical controls. This data suggests Ampligen's differentiated mechanism of activating innate immunity could complement targeted therapies like daraxonrasib, which showed a median overall survival of 13.2 months in a pivotal study. The company is also evaluating Ampligen in combination therapy with checkpoint inhibitors, with topline results from the DURIPANC Phase 2 trial anticipated in Q1 2027.

Disclaimer*

UK 100

Latest directors dealings